Note: "Godmen gillmen" appears to be a phonetic mis-transcription of Goodman & Gilman's (the classic pharmacology textbook). The answer below synthesizes content from Bradley & Daroff's Neurology, Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Stahl's Essential Psychopharmacology, Goldman-Cecil Medicine, and current literature.

Drug-Induced Parkinsonism (DIP)

Definition

Pathophysiology

Causative Drugs

Most Common Causes

1. Typical (first-generation) antipsychotics - haloperidol, fluphenazine, perphenazine, chlorpromazine (high-potency > low-potency agents)
2. Antidopaminergic antiemetics - metoclopramide, prochlorperazine
3. Dopamine-depleting agents - reserpine, tetrabenazine, deutetrabenazine, valbenazine

Atypical Antipsychotics (ranked by DIP risk, highest to lowest):

Risperidone = Ziprasidone > Olanzapine > Quetiapine > Clozapine

Other Drugs Associated with DIP

• SSRIs (selective serotonin reuptake inhibitors)
• Lithium
• Valproic acid
• Phenytoin
• Methyldopa
• Aripiprazole and newer atypical neuroleptics
• Calcium channel blockers: flunarizine, cinnarizine

Clinical Features

• Muscular rigidity - either "lead pipe" (continuous) or "cogwheel" (ratchet-like, discontinuous)
• Akinesia/bradykinesia - psychomotor retardation, masked facies, shuffling gait, decreased arm swing, slowed speech, micrographia
• Resting tremor - rhythmic 3-6 Hz oscillations, can be unilateral or symmetrical, affecting head, tongue, jaw, limbs

• Signs are usually symmetrical in DIP (asymmetric in idiopathic PD)
• Tremor is more often postural than classic resting tremor in DIP
• Positive glabella tap sign on examination
• History of offending drug exposure

Onset and Time Course

• Typically appears subacutely after weeks to months of therapy (commonly within the first 5 to 30 days for antipsychotics)
• Can appear after dose increase or after reduction of antiparkinsonian agents
• Only 1 of the 3 cardinal features is required for diagnosis

Risk Factors

• Increasing age (incidence higher in those >60 years)
• Higher drug dose
• Female sex (women more susceptible than men)
• Pre-existing history of parkinsonism
• Underlying basal ganglia damage

Relationship to Idiopathic Parkinson Disease

• The clinical presentation of antipsychotic-induced parkinsonism and idiopathic PD are indistinguishable - patients with subclinical PD often worsen dramatically on antipsychotics
• Patients taking neuroleptics may be 5 times more likely to eventually start antiparkinsonian medications than non-users
• If symptoms do not resolve after drug discontinuation, the drug likely unmasked underlying PD
• Occasionally, discontinuing the offending dopamine receptor blocker causes tardive dyskinesia to emerge
• CSF levels of dopamine catabolites are reduced in both idiopathic PD and DIP

Treatment

• Reduce dose or discontinue the offending agent
• Switch from high-potency D2 blocker (e.g., fluphenazine) to:
  • Lower-potency FGA (e.g., perphenazine), or
  • SGA such as quetiapine, lumateperone, or aripiprazole (partial D2/D3 agonists)

• Anticholinergics work by restoring the dopamine-acetylcholine balance in the basal ganglia
• Levodopa and dopamine agonists can also improve most features, though may be less effective for severe neuroleptic-induced tremor
• Preliminary data also support oral DHEA as adjunctive therapy

• Usually resolves with drug cessation, but may take up to 6 months for full resolution
• Once EPS are controlled, gradual withdrawal of antiparkinsonian medications can be attempted without EPS recurrence in some patients

Summary Table

Centrally Acting Anticholinergics in Parkinson's Disease

The Core Concept: Dopamine-Acetylcholine Balance

• Dopaminergic neurons from the substantia nigra project to the striatum and act on D2 receptors to inhibit acetylcholine release from cholinergic interneurons
• This normally maintains a balance between the inhibitory dopaminergic input and the excitatory cholinergic discharge

• Dopaminergic neurons are lost (idiopathic PD) OR dopamine is blocked/depleted (DIP)
• Without dopamine's inhibitory effect, cholinergic interneurons are disinhibited - acetylcholine release increases unchecked
• This relative cholinergic excess over dopamine leads to the motor symptoms: tremor, rigidity, bradykinesia, and akinesia

Why "Centrally Acting" is Essential

Mechanism at the Circuit Level (Stahl's)

Dopamine neurons in the nigrostriatal motor pathway make postsynaptic connections on cholinergic interneurons. Dopamine acting at D2 receptors normally inhibits acetylcholine release from postsynaptic nigrostriatal cholinergic neurons. When D2 blockers are given (or dopamine neurons are lost), dopamine can no longer suppress acetylcholine release, thus disinhibiting acetylcholine release. This leads to more excitation of postsynaptic muscarinic M1 receptors on medium spiny GABAergic neurons, which inhibits movements, producing akinesia, bradykinesia, rigidity, and tremor.

When this enhanced acetylcholine release is blocked by anticholinergics at muscarinic receptors, this restores in part the normal balance between dopamine and acetylcholine and reduces DIP.

Drugs - The Key Agents

Clinical Indications in Parkinsonism

1. Drug-induced parkinsonism (DIP) - when the offending antipsychotic cannot be stopped
2. Idiopathic Parkinson's disease - as adjunctive therapy, especially for tremor and drooling (less effective for bradykinesia/rigidity compared to levodopa)
3. Postencephalitic parkinsonism
4. Acute dystonic reactions - benztropine IM/IV is highly effective
5. Akathisia - partial benefit
6. Combined with levodopa - can have a more effective response than either alone in idiopathic PD

These drugs are less effective than levodopa for overall motor symptoms, but are particularly useful for tremor and when dopaminergic therapy is not yet required or not tolerated.

Advantages Over Levodopa (In Specific Contexts)

• No "on-off" phenomenon
• No dyskinesias
• Useful when tremor is the predominant symptom and rigidity/bradykinesia are mild
• Can be used when levodopa is not yet indicated (early disease with mainly tremor)
• Useful in drug-induced parkinsonism where you cannot simply give more dopamine

Adverse Effects (Why Caution is Required)

Central (CNS) Effects

• Cognitive impairment and memory loss - via M1/M2/M4 blockade in hippocampus and neocortex
• Anticholinergic delirium - especially in elderly
• Worsening psychosis in acutely ill schizophrenic patients
• May worsen tardive dyskinesia (TD) - anticholinergics shift the DA-ACh balance further toward dopamine dominance, potentially worsening TD; the incidence of TD is higher when both neuroleptic and anticholinergic medications are co-administered

Peripheral Effects (classic anticholinergic)

• Dry mouth (xerostomia)
• Blurred vision / cycloplegia
• Urinary retention
• Constipation
• Tachycardia
• Decreased sweating (risk of heat stroke)

Goodman & Gilman's: "Elderly patients are at greatest risk for parkinsonism and are most sensitive to the cognitive and peripheral adverse effects of anticholinergic antiparkinsonian medications."

Contraindications

Important Pharmacokinetic Note

The anticholinergic activity is independent of serum drug levels because levels vary up to 100-fold. A threshold serum level for anticholinergic activity exists - once achieved, EPS are unlikely to occur. The reduction in EPS is NOT related to the dose of the anticholinergic or the dose of the antipsychotic, but only to the achieved serum level of anticholinergic activity. - Kaplan & Sadock's

Summary: Why Centrally Acting Anticholinergics Matter in Parkinson's

1. Mechanism: Restore the dopamine-acetylcholine balance in the striatum by blocking M1 muscarinic receptors on medium spiny neurons, reducing cholinergic overactivity caused by dopamine deficiency
2. Efficacy: Best for tremor and drooling; less effective than levodopa for bradykinesia/rigidity
3. Unique role: The only oral option when DIP cannot be reversed by stopping the causative drug; also useful for acute dystonia (IM/IV)
4. Limitation: Cognitive side effects limit their use in elderly patients and those with dementia - in these populations, amantadine is preferred over anticholinergics
5. Risk: Prolonged use alongside neuroleptics may increase the risk of TD development, so they should be minimized or avoided in long-term neuroleptic therapy